Related Experiment Videos
ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines
Trina J Stewart1, Debbie Drane, Jim Malliaros
1Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
Vaccine
|August 19, 2004
Summary
This study shows that the ISCOMATRIX adjuvant effectively stimulates immune responses against Human Papillomavirus type 16 (HPV16) E6E7 proteins in mice. This adjuvant is preferred for cancer immunotherapy when cell-mediated immunity is desired.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Human Papillomavirus type 16 (HPV16) oncoproteins E6 and E7 are key drivers of cervical cancer.
- These oncoproteins serve as potential targets for cancer immunotherapy development.
Purpose of the Study:
- To evaluate the immunogenicity of different vaccine formulations using recombinant HPV16 E6E7 or E7GST fusion proteins in mice.
- To compare the efficacy of ISCOMATRIX adjuvant versus aluminum hydroxide (Al(OH)3) adjuvant.
Main Methods:
- Vaccine formulations with recombinant HPV16 E6E7 or E7GST fusion proteins were tested in mice.
- Immunogenicity was assessed by measuring E7 specific CTL, antibody, and DTH responses.
- In vivo tumor protection was evaluated.
Main Results:
- ISCOMATRIX adjuvant with E6E7 proteins induced robust E7 specific CTL, antibody, DTH responses, and tumor protection.
- Aluminum hydroxide adjuvant elicited lower antibody and no local CTL responses, but similar DTH and tumor protection.
- ISCOMATRIX demonstrated superior ability to stimulate both cellular and humoral immunity.
Conclusions:
- ISCOMATRIX adjuvant is effective in stimulating cellular (CTL) and humoral immune responses against endogenously processed antigens like HPV16 E6E7.
- ISCOMATRIX is the preferred adjuvant for cancer immunotherapy strategies aiming to induce CTL responses.